Peregrine Ventures

"DairyX attempts to more precisely replicate the process taking place in a cow, in which casein undergoes post-translational modifications that impact the formation and stability of casein micelles and can significantly alter their functionality in food applications..." – AgFunder 🧀✨ Thank you, Elaine Watson, for featuring DairyX’s latest progress in AgFunder! I appreciate how you follow us pushing forward with animal-free casein production through precision fermentation. This is an important milestone for us as we keep striving to create more sustainable, dairy-like products. 🌍💡 Check out the full article here: 👉https://lnkd.in/d3YYbu4e #FoodTech #Sustainability #Innovation #PrecisionFermentation #AnimalFree #DeepTech

We're excited to share that our new website is now live! 🎉 Our new look represents the next chapter for BRAIN.Q, highlighting our commitment to innovation and excellence.  Alongside the fresh design, we’re excited to share a view into the science behind #EMAGINE.II, our latest clinical trial aimed at advancing stroke recovery. Explore the new site to learn more about our mission, our cutting-edge technology, and the impact of our ongoing research. Take a look around and let us know your thoughts! Visit: brainqtech.com Hanaco Ventures Peregrine Ventures OurCrowd Michael Eisenberg Eilon Tirosh Assaf Harlap אסף חרל״פ Amir Gross Ilan Oren Pasha Romanovski Dexcel Pharma Stacey Pugh

Last weekend we reached another milestone in our journey to bring women around the world with our groundbreaking solution for Female #Androgenetic #Alopecia. We landed in China to train the first doctors in preforming the HAIRSTETICS procedure. It was an amazing training and event that brought light, air (and some hair) to our mind in these challenging times. Wish to thank all our employees, partners, and founders for their constant efforts and support. Peregrine Ventures Boaz Shenhav Dvir Keren Gilles BOS Silvia Scherer

Today we are honored to announce a global license agreement with Immunome, Inc. Under the terms of the license, Immunome received exclusive rights to a panel of antibodies targeting a novel undisclosed target. “This agreement allows Nectin Therapeutics to realize value while further pursuing and enabling the focus on our first-in-class anti-PVR program (NTX1088) through its ongoing clinical study in tumor types with high unmet need, in parallel to advancing our novel #ADCs into clinical development. Immunome’s leadership team’s track record of developing and commercializing novel ADC therapies makes it an ideal partner to advance these promising assets,” said Fabian Tenenbaum, Chief Executive Officer of Nectin Therapeutics. “Immunome believes the next generation of transformative antibody-drug conjugates will address novel targets by pairing high-quality antibodies with innovative linker-payload technology,” said Clay Siegall, PhD, President and Chief Executive Officer of Immunome. “We appreciate the work Nectin has done on these antibodies and look forward to advancing them further.” To read about the news: https://lnkd.in/g68U9GBf #CancerResearch #Immunotherapy #Biotechnology

A big thank you to Christopher Kellner, MD, the national PI for the TORNADO study, for his presentation at the SNIS Annual Meeting in Colorado Springs earlier this week. It's exciting to see the TORNADO study surpassing 80% enrollment, marking a key milestone in our efforts to improve treatment for wide neck aneurysms. Dr. Kellner's insights on the Nautilus Intrasaccular System highlight its potential as a new approach in the field. Thank you, Dr. Kellner, for your leadership and dedication. We're looking forward to the continued progress of this important work! #Nautilus #SNIS2024 #Neuroscience #Innovation #MedicalResearch

Eyal Lifschitz is an entrepreneur and investor with years of experience in establishing and managing life science companies and their business development efforts. Lifschitz serves as the Co-founder and Managing General Partner of Peregrine Ventures, a global life science venture capital fund dedicated to improving patients' quality of life by investing in and supporting life changing healthcare opportunities. In this role, he oversees all daily operations and mentors entrepreneurs on their journeys to bring innovative medical technologies to market. On behalf of Peregrine, Lifschitz serves on the boards of Momentis Surgical, Nectin Therapeutics, Restore Medical, Kahr Medical, Cordio Medical, Raziel Therapeutics and others. Previously, Lifschitz was involved as a founder and a manager in PharmaSys (acquired by Elan Corp. NYSE: ELN), ECR (acquired by AVX Corp. NYSE: AVX), Visioncare Ophthalmic Technologies, BioControl, and as a director of Given Imaging (NASDAQ: GIVN). Lifschitz serves as Chairman in the Israeli Early-Stage Investors Association (IEI) & Technology Incubator Forum (ITIF) which promotes Israeli high-tech ventures both domestically and abroad. Lifschitz is also a Founder and Chairman of GamVeGam, a non-for-profit cooperation between the Israeli Ministry of Education and the Israeli high-tech industry which aims to encourage high-tech professionals to become teachers in public schools, and he also serves on the Board of Trustee at Bar Ilan University. Meet Eyal Lifschitz @ #Sachs_HTIF More Info @ https://lnkd.in/df5auS9k #HealthTech #DigitalHealth #MedTech #HealthTechInnovation #BigData #AI #HealthTechForum #PharmaTechnology #MedicalDevices #HealthcareTechnology #HealthTechInvestment #SALSW

𝗜𝗿𝗼𝗻 𝗡𝗮𝘁𝗶𝗼𝗻 𝗯𝗮𝗰𝗸𝘀 𝗖𝗼𝗿𝗱𝗶𝗼 𝘁𝗼 𝗧𝗿𝗮𝗻𝘀𝗳𝗼𝗿𝗺 𝗥𝗲𝗺𝗼𝘁𝗲 𝗛𝗲𝗮𝗹𝘁𝗵 𝗠𝗼𝗻𝗶𝘁𝗼𝗿𝗶𝗻𝗴 𝗨𝘀𝗶𝗻𝗴 𝗩𝗼𝗶𝗰𝗲 𝗔𝗻𝗮𝗹𝘆𝘀𝗶𝘀 𝗧𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝘆 Iron Nation is thrilled to  announce its investment in Cordio Medical, an innovative company that provides medical-grade solutions to monitor health conditions by applying sophisticated and proprietary algorithms to analyze patient voice samples recorded on a smartphone app. This technology enables remote, near real-time monitoring and early detection of patient condition deterioration. 𝗧𝗮𝗺𝗶𝗿 𝗧𝗮𝗹, CEO of Cordio Medical: “Iron Nation investment will help Cordio gain FDA approval for our innovative heart failure remote monitoring tool, potentially improving the lives and reducing mortality rates for millions of patients”. Gil Friedlander, Iron Nation managing partner: “Cordio Medical is another example of an inspiring team and amazing Israeli technology. Their groundbreaking voice analysis technology has the potential to be a game-changer in ‘democratizing’ remote patient monitoring, improve early detection of health issues, and ultimately save lives around the world." Special thanks to Dr. Irit Yaniv from Almeda Ventures for her invaluable guidance during the Cordio Medical due diligence process! Gil Friedlander Chen Linchevski Jason Wolf Sivan Goltzman Ilan Tevet Chemi Peres Calanit Valfer Moshe Lichtman Daniel Cohen Charlie Federman Aaron Applbaum Rony Patishi-Chillim Eilon Tirosh  Dr. Ami Appelbaum  Haim Shani  Ronen Nir  Eyal Lifschitz Izhar Shay #healthcareinnovation #digitalhealth #remotepatientmonitoring #earlydetection